What the FDA Announced on April 15, 2026 The federal notice issued on April 15, 2026, makes two concurrent procedural announcements
Semaglutide's cognitive benefits appear to stem from stabilized blood sugar, reduced inflammation, and improved cerebral blood flownot weight loss alone
26 This trial also showed no change in wall motion score index at any stress levels and no change in global longitudinal strain or global longitudinal strain rate at rest
One is Virta Health, which advertises its nutrition-focused weight management program as "a proven approach for deprescribing GLP-1s when clinically appropriate." A Virta-funded study assessed 154 people with Type 2 diabetes who stopped using GLP-1 medications but continued following Virta's program, concluding that their weight did not significantly increase after a year
If transparent pricing and pharmacy choice are your priority, Pomegranate is one of the strongest options in the category